Coronavirus business update Get 30 days’ complimentary access to our Coronavirus Business Update newsletter 30 days complimentary
Add this topic to your myFT Digest for news straight to your inbox
Experimental inoculation elicits ‘robust’ immune response when used on animals
In the battle between public science and anti-vaxxer sentiment, science is heavily outgunned
Drugmaker believes its potential Covid-19 vaccine ‘can be distributed in a very reasonable way’
Coronavirus exposed widespread exploitation of migrant labour
Advance purchase agreement depends on clinical trials starting in September
Kate Bingham of government task force plays down hopes of lifetime immunity despite recent positive trial results
President Macron says state is prepared to invest in reshoring, starting with paracetamol
Price charged to governments would be higher than that agreed for rival jabs from Pfizer and BioNTech
Social media platform says president’s son promoted ‘misinformation’ about virus and hydroxychloroquine
Albert Bourla warns US president’s orders on drug pricing reform put scientists’ jobs at risk
Shares rise after 30,000 participants get their phase-three jabs
Spending spree stokes wrangles over pricing and risks leaving behind poorer nations
Doses secured to inoculate 30m people, which will also be offered to over-50s in England for first time
Questions over immunity and eligibility and lack of clear strategy leave manufacturers in limbo
Matt Hancock ready to reform PHE as criticism of its response to coronavirus crisis mounts
BioNTech and Pfizer announce deal for 100m doses of coronavirus inoculation candidate
Vladimir Putin suggests country has weathered worst of pandemic, but virus not yet in retreat
Quest Diagnostics executive says ‘no way’ capacity will expand enough to cope with flu season
UK secures 90m doses, GSK buys stake in CureVac and Oxford/AstraZeneca trial shows promise
Injection developed with AstraZeneca generates ‘robust immune responses’
UK agrees to buy potential coronavirus inoculations from BioNTech and Valneva
Deal increases UK drugmaker’s exposure to potential coronavirus vaccines
A rise in cases is dashing hopes that the continent’s younger population would spare it from the worst of coronavirus
Kirill Dmitriev says his country will be among those to develop a vaccine soon
UK, US and Canada attribute attacks to group ‘almost certainly’ working for Moscow
